October 12 (Wed)
October 13 (Thu)
October 14 (Fri)
| Time | Program | Speaker | Affilliation |
|---|---|---|---|
| 08:00~09:00 | Registration | ||
| 09:00~09:30 | Opening Ceremony | ||
| PL 1 : Continued success of Xcopri development: NDA, subsequent development and commercialization | |||
| 09:30~10:00 | Plenary Lecture 1 | Chair : In-Jin Jang | |
| 09:30~10:00 | Continued success of XCOPRI® development: NDA, subsequent development and commercialization | Jeong-Woo Cho | SK Biopharmaceuticals Co., Ltd. |
| 10:00~10:30 | Coffee Break | ||
| PS 1 Talkshow: Creating global success of drug development in extremely competitive environment | |||
| 10:30~12:00 | Plenary Session1 | Chair : Hanlim Moon | |
| 10:30~12:00 | PS 1 Talkshow: Creating global success of drug development in extremely competitive environment | - - | - |
| 10:30~12:00 | ┗━ Special Panel : Byoungjun Bae(KoNECT), Myungjin Jung(Financial News) / Panel : Healthcare Discovery - Youngki Shin(Abion), Branden Ryu(BIORCHESTRA) | ||
| 10:30~12:00 | ┗━ Panel : Clinical Development - Seung-Jae Baek(Hanmi Pharm Co. Ltd) , Se-Woong Oh(Yuhan Corporation) / Commercial - Geun-Seog Song(HK inno.N Corp.), Hyeokjae Lee(Celltrion) | ||
| 12:00~13:30 | Lunch | ||
| S1 : Patient-Centric Drug Development & S4 : Drug Delivery to the Target Tissue | |||
| 13:30~15:00 | S1: Patient-Centric Drug Development | Chair : BG Rhee, Yu-Kyeong Hwang |
|
| 13:30~13:50 |
Patient-Centric CAR-T Development
|
Dong-Hyuk Jeon | CUROCELL |
| 13:50~14:10 |
Symptom-specific control of movement disorders by CaV3.2 ASO
|
Daesoo Kim | KAIST |
| 14:10~14:30 |
Genetic Medicine with Non-viral Delivery Technology
|
Yoonchul Shin | GenEdit |
| 14:30~14:50 | Open Discussion | ||
| 14:50~15:00 | Q&A | ||
| 15:00~15:30 | Coffee Break | ||
| 15:30~17:00 | S4: Drug Delivery to the Target Tissue | Chair : Jinsan Yoo, Jong-Seo Lee |
|
| 15:30~15:50 | Overcoming the Blood-Brain Barrier for RNA therapeutics | Mi Jung Lim | BIORCHESTRA Co., Ltd. |
| 15:50~16:10 | Brain Somatic Mutations as RNA Therapeutic Targets in Neurological Disorders | Jeong-Ho Lee | SoVarGen/KAIST |
| 16:10~16:30 | BBB Shuttle by Aptamer Technology | Daekyun Lee | Aptamer Sciences |
| 16:30~17:00 |
New era of mRNA Therapeutics
|
Hyun-Bae Jie | Levatio Therapeutics |
| 17:00~17:30 | Open Discussion | ||
| S2 : Creating Comprehensive Drug Development Plan: Strategic Planning through the Product Lifecycle & S5 : Creating Comprehensive Drug Development Plan | |||
| 13:30~15:00 | S2 : Creating Comprehensive Drug Development Plan: Strategic Planning through the Product Lifecycle | Chair : Mi-Young Bahng, Jungshin Park |
|
| 13:30~14:00 |
Begin with end in mind: Target product profile and clinical development plan
|
Nari Yun | GI Innovation |
| 14:00~14:30 | Orphan Drug and Expedited Drug Development Programs in US/EU | Hye Jin Choi | IQVIA |
| 14:30~15:00 | Global & Market Expansion of K-CAB | Eunji Kim | HK inno.N |
| 15:00~15:30 | Coffee Break | ||
| 15:30~17:00 | S5 : Creating Comprehensive Drug Development Plan: Strategic Planning through Multifunctional Integration | Chair : Myunghoon Kim, Sora Lee |
|
| 15:30~15:50 | Marketing principles applied to clinical development | Seungwon Jeong | Hanall Bio |
| 15:50~16:10 |
Clinical Trial Design for Regulatory and Commercial Success
|
Miyoung Kim | LG Chemical Life Sciences |
| 16:10~16:30 |
Biostatistical Validation of Protocol for Clinical and Commercial Success
|
Sang Joon Lee | Celltrion |
| 16:30~16:45 |
How to Incorporate Market Access Strategy to Clinical Trials
|
Yuri Lee | AMGEN |
| 16:45~17:00 | Q&A and Pannel Discussion | ||
| S3 : Understanding Market and Investment Theory & S6: Practical Investment Guide based on Real Cases | |||
| 13:30~15:00 | S3 : Understanding Market and Investment Theory | Chair : Myungkee Kim | |
| 13:30~13:50 |
Global/Korean Life Science Investment Market Trend
|
Min Sik Shin | KB Investment |
| 13:50~14:10 |
Selecting the Right Biotech Company to Invest
|
Aleum Lee | IMM Investment |
| 14:10~14:30 | Opportunities Created by a Bear Market | Ted Moon | RM Global Partners |
| 14:30~14:50 |
Healthcare Company IPO Trends & Technology Assessment Listing Track Strategies
|
Wonje Kim | Samsung Securities Co., Ltd |
| 14:50~15:00 | Q&A | ||
| 15:30~17:00 | S6 : Practical Investment Guide based on Real Cases | Chair : Minsik Park | |
| 15:30~16:00 | IPO by Technology Assessment Listing | Jung-Sun Yum | CHA Vaccine Institute |
| 16:00~16:25 |
Listing Experiences in the KONEX & KOSDAQ - Genome & Company
|
Youngjin Seo | Genome & Company |
| 16:25~16:50 |
IPO by Special Purpose Acquisition Company (SPAC)
|
Kisub Lee | Kainos Medicine |
| 16:50~17:00 | Q&A | ||
.png&folder=site)